Distinct tyrosine autophosphorylation sites negatively and positively modulate neu-mediated transformation

A number of cytoplasmic signaling molecules are thought to mediate mitogenic signaling from the activated Neu receptor tyrosine kinase through binding specific phosphotyrosine residues located within the intracellular portion of Neu/c-ErbB-2. An activated neu oncogene containing tyrosine-to-phenylalanine substitutions at each of the known autophosphorylation sites was generated and assessed for its specific transforming potential in Rat1 and NIH 3T3 fibroblasts. Mutation of these sites resulted in a dramatic impairment of the transforming potential of neu. To assess the role of these tyrosine phosphorylation sites in cellular transformation, the transforming potential of a series of mutants in which individual tyrosine residues were restored to this transformation-debilitated neu mutant was evaluated. Reversion of any one of four mutated sites to tyrosine residues restored wild-type transforming activity. While each of these transforming mutants displayed Ras-dependent signaling, the transforming activity of two of these mutants was correlated with their ability to bind either the GRB2 or SHC adapter molecules that couple receptor tyrosine kinases to the Ras signaling pathway. By contrast, restoration of a tyrosine residue located at position 1028 completely suppressed the basal transforming activity of this mutated neu molecule or other transforming neu molecules which possessed single tyrosine residues. These data argue that the transforming potential of activated neu is mediated both by positive and negative regulatory tyrosine phosphorylation sites.

[1]  M. Shibuya,et al.  Tyrosine phosphorylation sites at amino acids 239 and 240 of Shc are involved in epidermal growth factor-induced mitogenic signaling that is distinct from Ras/mitogen-activated protein kinase activation , 1997, Molecular and cellular biology.

[2]  M. Moran,et al.  Requirement for the Adapter Protein GRB2 in EGF Receptor Endocytosis , 1996, Science.

[3]  N. Perrimon,et al.  Drosophila terminal structure development is regulated by the compensatory activities of positive and negative phosphotyrosine signaling sites on the Torso RTK. , 1996, Genes & development.

[4]  G. Apell,et al.  Affinity, Specificity, and Kinetics of the Interaction of the SHC Phosphotyrosine Binding Domain with Asparagine-X-X-Phosphotyrosine Motifs of Growth Factor Receptors (*) , 1996, The Journal of Biological Chemistry.

[5]  A. Ullrich,et al.  Transforming potentials of epidermal growth factor and nerve growth factor receptors inversely correlate with their phospholipase C gamma affinity and signal activation. , 1996, The EMBO journal.

[6]  P. Pelicci,et al.  Analysis of protein-protein interactions involved in the activation of the Shc/Grb-2 pathway by the ErbB-2 kinase. , 1995, Oncogene.

[7]  O. Witte,et al.  Alternative signals to RAS for hematopoietic transformation by the BCR-ABL oncogene , 1995, Cell.

[8]  B. Margolis,et al.  The phosphotyrosine interaction domain of Shc binds an LXNPXY motif on the epidermal growth factor receptor , 1995, Molecular and cellular biology.

[9]  W. Muller,et al.  Direct and specific interaction of c-Src with Neu is involved in signaling by the epidermal growth factor receptor. , 1995, Oncogene.

[10]  C. Turck,et al.  PTB domain binding to signaling proteins through a sequence motif containing phosphotyrosine. , 1995, Science.

[11]  K. Siminovitch,et al.  Recruitment and activation of PTP1C in negative regulation of antigen receptor signaling by Fc gamma RIIB1. , 1995, Science.

[12]  T. Pawson,et al.  A conserved amino-terminal Shc domain binds to phosphotyrosine motifs in activated receptors and phosphopeptides , 1995, Current Biology.

[13]  Ursula Klingmüller,et al.  Specific recruitment of SH-PTP1 to the erythropoietin receptor causes inactivation of JAK2 and termination of proliferative signals , 1995, Cell.

[14]  Peer Bork,et al.  A phosphotyrosine interaction domain , 1995, Cell.

[15]  L. Williams,et al.  Binding of NCK to SOS and activation of ras-dependent gene expression , 1995, Molecular and cellular biology.

[16]  Tony Pawson,et al.  Protein modules and signalling networks , 1995, Nature.

[17]  N. Hynes,et al.  The biology of erbB-2/neu/HER-2 and its role in cancer. , 1994, Biochimica et biophysica acta.

[18]  B. Margolis,et al.  A region in Shc distinct from the SH2 domain can bind tyrosine-phosphorylated growth factor receptors. , 1994, The Journal of biological chemistry.

[19]  A. deFazio,et al.  Activation of the Ras signalling pathway in human breast cancer cells overexpressing erbB-2. , 1994, Oncogene.

[20]  W. Muller,et al.  Novel activating mutations in the neu proto-oncogene involved in induction of mammary tumors. , 1994, Molecular and cellular biology.

[21]  C. Heldin,et al.  Tyr-716 in the platelet-derived growth factor beta-receptor kinase insert is involved in GRB2 binding and Ras activation , 1994, Molecular and cellular biology.

[22]  T Pawson,et al.  Formation of Shc-Grb2 complexes is necessary to induce neoplastic transformation by overexpression of Shc proteins. , 1994, Oncogene.

[23]  M. Matsuda,et al.  CRK protein binds to two guanine nucleotide-releasing proteins for the Ras family and modulates nerve growth factor-induced activation of Ras in PC12 cells , 1994, Molecular and cellular biology.

[24]  D. Stacey,et al.  Cellular ras activity is required for passage through multiple points of the G0/G1 phase in BALB/c 3T3 cells , 1994, Molecular and cellular biology.

[25]  J. Schlessinger,et al.  Hierarchy of binding sites for Grb2 and Shc on the epidermal growth factor receptor , 1994, Molecular and cellular biology.

[26]  Y. Yarden,et al.  A single autophosphorylation site confers oncogenicity to the Neu/ErbB‐2 receptor and enables coupling to the MAP kinase pathway. , 1994, The EMBO journal.

[27]  T Pawson,et al.  Specific motifs recognized by the SH2 domains of Csk, 3BP2, fps/fes, GRB-2, HCP, SHC, Syk, and Vav , 1994, Molecular and cellular biology.

[28]  P. D’Eustachio,et al.  The SH2 domain protein GRB‐7 is co‐amplified, overexpressed and in a tight complex with HER2 in breast cancer. , 1994, The EMBO journal.

[29]  M. Luther,et al.  Involvement of pp60c-src with two major signaling pathways in human breast cancer. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[30]  M. Shibuya,et al.  Epidermal growth factor-receptor mutant lacking the autophosphorylation sites induces phosphorylation of Shc protein and Shc-Grb2/ASH association and retains mitogenic activity. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[31]  W. Muller,et al.  Mammary tumors expressing the neu proto-oncogene possess elevated c-Src tyrosine kinase activity , 1994, Molecular and cellular biology.

[32]  P. Ravdin,et al.  Prognostic factors in early breast carcinoma , 1994, Cancer.

[33]  Jonathan A. Cooper,et al.  A new function for a phosphotyrosine phosphatase: linking GRB2-Sos to a receptor tyrosine kinase , 1994, Molecular and cellular biology.

[34]  T. Pawson,et al.  Shc products are substrates of erbB-2 kinase. , 1993, Oncogene.

[35]  M. Wigler,et al.  Human Sos1: a guanine nucleotide exchange factor for Ras that binds to GRB2. , 1993, Science.

[36]  Julian Downward,et al.  Epidermal growth factor regulates p21 ras through the formation of a complex of receptor, Grb2 adapter protein, and Sos nucleotide exchange factor , 1993, Cell.

[37]  D. Bar-Sagi,et al.  Grb2 mediates the EGF-dependent activation of guanine nucleotide exchange on Ras , 1993, Nature.

[38]  Nanxin Li,et al.  Guanine-nucleotide-releasing factor hSos1 binds to Grb2 and links receptor tyrosine kinases to Ras signalling , 1993, Nature.

[39]  T. Pawson,et al.  The SH2 and SH3 domains of mammalian Grb2 couple the EGF receptor to the Ras activator mSos1 , 1993, Nature.

[40]  R. Weinberg,et al.  Association of Sos Ras exchange protein with Grb2 is implicated in tyrosine kinase signal transduction and transformation , 1993, Nature.

[41]  A. Kazlauskas,et al.  Phospholipase C-γ1 and phosphatidylinositol 3 kinase are the downstream mediators of the PDGF receptor's mitogenic signal , 1993, Cell.

[42]  A. Ullrich,et al.  Activation of a phosphotyrosine phosphatase by tyrosine phosphorylation. , 1993, Science.

[43]  T. Pawson,et al.  SH2 domains recognize specific phosphopeptide sequences , 1993, Cell.

[44]  D. Lowy,et al.  Function and regulation of ras. , 1993, Annual review of biochemistry.

[45]  Sheila M. Thomas,et al.  Association of the Shc and Grb2/Sem5 SH2-containing proteins is implicated in activation of the Ras pathway by tyrosine kinases , 1992, Nature.

[46]  D. Ron,et al.  pGSTag--a versatile bacterial expression plasmid for enzymatic labeling of recombinant proteins. , 1992, BioTechniques.

[47]  R. Cardiff,et al.  Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[48]  T. Pawson,et al.  Shc proteins are phosphorylated and regulated by the v-Src and v-Fps protein-tyrosine kinases. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[49]  V. Brown,et al.  Carboxyl-terminal deletion and point mutations decrease the transforming potential of the activated rat neu oncogene product. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[50]  T. Pawson,et al.  A novel transforming protein (SHC) with an SH2 domain is implicated in mitogenic signal transduction , 1992, Cell.

[51]  K. Helin,et al.  erbB-2 autophosphorylation is required for mitogenic action and high-affinity substrate coupling. , 1992, Oncogene.

[52]  A. Ullrich,et al.  Tyrosine phosphatase inhibition permits analysis of signal transduction complexes in p185HER2/neu-overexpressing human tumor cells. , 1992, The Journal of biological chemistry.

[53]  A. Reith,et al.  SH2 domains of the p85 alpha subunit of phosphatidylinositol 3-kinase regulate binding to growth factor receptors , 1992, Molecular and cellular biology.

[54]  C. Molloy,et al.  The erbB-2 mitogenic signaling pathway: tyrosine phosphorylation of phospholipase C-gamma and GTPase-activating protein does not correlate with erbB-2 mitogenic potency , 1991, Molecular and cellular biology.

[55]  T. Akiyama,et al.  The transforming potential of the c-erbB-2 protein is regulated by its autophosphorylation at the carboxyl-terminal domain , 1991, Molecular and cellular biology.

[56]  S. Aaronson,et al.  The carboxy-terminal domains of erbB-2 and epidermal growth factor receptor exert different regulatory effects on intrinsic receptor tyrosine kinase function and transforming activity , 1990 .

[57]  S. Aaronson,et al.  The carboxy-terminal domains of erbB-2 and epidermal growth factor receptor exert different regulatory effects on intrinsic receptor tyrosine kinase function and transforming activity. , 1990, Molecular and cellular biology.

[58]  H. Land,et al.  A series of mammalian expression vectors and characterisation of their expression of a reporter gene in stably and transiently transfected cells. , 1990, Nucleic acids research.

[59]  J. Pierce,et al.  The role of autophosphorylation in modulation of erbB-2 transforming function. , 1990, The New biologist.

[60]  A. Ullrich,et al.  Identification of autophosphorylation sites of HER2/neu. , 1990, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[61]  P. Jolicoeur,et al.  Stochastic appearance of mammary tumors in transgenic mice carrying the MMTV/c-neu oncogene , 1989, Cell.

[62]  D. Weiner,et al.  A point mutation in the neu oncogene mimics ligand induction of receptor aggregation , 1989, Nature.

[63]  W Godolphin,et al.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.

[64]  B. Angus,et al.  Epidermal growth factor receptor status of histological sub-types of breast cancer. , 1988, British Journal of Cancer.

[65]  Cori Bargmann,et al.  Increased tyrosine kinase activity associated with the protein encoded by the activated neu oncogene. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[66]  P. Leder,et al.  Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene , 1988, Cell.

[67]  M. Roussel,et al.  Transforming potential of the c-fms proto-oncogene (CSF-1 receptor) , 1987, Nature.

[68]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.

[69]  Cori Bargmann,et al.  The neu oncogene encodes an epidermal growth factor receptor-related protein , 1986, Nature.

[70]  Cori Bargmann,et al.  Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185 , 1986, Cell.

[71]  N. Nomura,et al.  Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor , 1986, Nature.

[72]  P. Seeburg,et al.  Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. , 1985, Science.

[73]  Robert A. Weinberg,et al.  Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies , 1985, Cell.

[74]  Richard Axel,et al.  Transfer of purified herpes virus thymidine kinase gene to cultured mouse cells , 1977, Cell.